by | May 14, 2025 | Oh, Youngmi, Yoo, Andrew
— Published Date: 5/14/2025
Value Proposition: Novel antisense oligonucleotide (ASO) directly targeting a microRNA-mediated mechanism responsible for autophagy reduction and neurodegeneration in Huntington’s disease (HD) improving patient outcomes in pre-HD subjects.
Technology Description
R…
by | May 13, 2025 | Cavalli, Valeria, Feng, Rui
— Published Date: 12/21/24
Value proposition: A cost-effective, drug-based therapy targeting the endothelin B receptor (ETBR) to promote peripheral nerve regeneration, offering improved recovery and compatibility with existing treatments.
Technology Description
Researchers at Washington University…
by | May 13, 2025 | Djuranovic, Sergej, Pirzada, Mujeeb
— Published Date: 5/14/2025
Value proposition: Novel ASOs that increase key protein production to limit neurodegeneration caused by ALS and frontotemporal dementia (FTD).
Technology Description
TDP-43 pathology is present in ~97% of ALS, ~50% of FTD, and frequently observed in other neurodegenerat…
by | Dec 19, 2024 | Chheda, Milan, Curiel, David, Diamond, Michael, Li, Yuping
— Published Date: 12/20/2024
Value Proposition: Treats brain tumors by combining a hematopoietic growth protein and cancer therapeutics to increase survival rates.
Technology Description
Researchers at Washington University in St. Louis have developed a new way to treat brain cancers by combining…
by | Dec 18, 2024 | Barthelemy, Nicolas, Bateman, Randall, He, Yingxin "Chloe", Horie, Kanta, Mukherjee, Soumya
— Published Date: 12/19/2024
Value proposition: Novel method used to detect tau proteins in the brain using biofluids.
Technology Description
Researchers at Washington University in St. Louis have developed a method to identify and differentiate primary and secondary tauopathies in the brain. Man…